Aprogen Pharmaceuticals Inc - Asset Resilience Ratio
Aprogen Pharmaceuticals Inc (003060) has an Asset Resilience Ratio of 4.32% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how Aprogen Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check Aprogen Pharmaceuticals Inc (003060) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Aprogen Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 003060 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩26.07 Billion | 4.32% |
| Total Liquid Assets | ₩26.07 Billion | 4.32% |
Asset Resilience Insights
- Limited Liquidity: Aprogen Pharmaceuticals Inc maintains only 4.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Aprogen Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Aprogen Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 15.57% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Aprogen Pharmaceuticals Inc (2009–2024)
The table below shows the annual Asset Resilience Ratio data for Aprogen Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.40% | ₩26.01 Billion ≈ $17.63 Million |
₩590.98 Billion ≈ $400.50 Million |
-6.63pp |
| 2022-12-31 | 11.03% | ₩75.46 Billion ≈ $51.14 Million |
₩684.14 Billion ≈ $463.63 Million |
-3.59pp |
| 2021-12-31 | 14.62% | ₩89.86 Billion ≈ $60.90 Million |
₩614.62 Billion ≈ $416.52 Million |
-8.18pp |
| 2020-12-31 | 22.80% | ₩140.28 Billion ≈ $95.07 Million |
₩615.31 Billion ≈ $416.99 Million |
-15.31pp |
| 2019-12-31 | 38.11% | ₩139.21 Billion ≈ $94.34 Million |
₩365.28 Billion ≈ $247.55 Million |
+19.30pp |
| 2018-12-31 | 18.81% | ₩40.83 Billion ≈ $27.67 Million |
₩217.06 Billion ≈ $147.10 Million |
+12.74pp |
| 2017-12-31 | 6.07% | ₩9.61 Billion ≈ $6.51 Million |
₩158.27 Billion ≈ $107.26 Million |
-18.88pp |
| 2016-12-31 | 24.95% | ₩32.11 Billion ≈ $21.76 Million |
₩128.69 Billion ≈ $87.21 Million |
+24.88pp |
| 2015-12-31 | 0.07% | ₩60.00 Million ≈ $40.66K |
₩85.22 Billion ≈ $57.75 Million |
-20.81pp |
| 2014-12-31 | 20.88% | ₩17.71 Billion ≈ $12.00 Million |
₩84.83 Billion ≈ $57.49 Million |
+15.70pp |
| 2013-12-31 | 5.19% | ₩4.06 Billion ≈ $2.75 Million |
₩78.26 Billion ≈ $53.04 Million |
+2.78pp |
| 2012-12-31 | 2.41% | ₩2.24 Billion ≈ $1.52 Million |
₩93.08 Billion ≈ $63.08 Million |
-2.00pp |
| 2011-12-31 | 4.41% | ₩5.13 Billion ≈ $3.48 Million |
₩116.33 Billion ≈ $78.84 Million |
+1.36pp |
| 2010-12-31 | 3.05% | ₩2.40 Billion ≈ $1.63 Million |
₩78.70 Billion ≈ $53.33 Million |
+0.27pp |
| 2010-09-30 | 2.78% | ₩1.88 Billion ≈ $1.27 Million |
₩67.64 Billion ≈ $45.84 Million |
+2.10pp |
| 2009-12-31 | 0.68% | ₩402.20 Million ≈ $272.57K |
₩59.07 Billion ≈ $40.03 Million |
-- |
About Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.